Organization plans study to test benefits of hormone
In an effort to help find a more effective treatment for individuals with type 1 diabetes, the Juvenile Diabetes Research Foundation recently announced that it will fund an investigation into the effectiveness of a new hormone therapy.
Researchers will conduct a clinical trial on the benefits of metreleptin, a hormone that has been shown in animal models to control many of the symptoms of type 1 diabetes. Researchers hope that the human testing will show similar benefits.
"If effective in humans, metreleptin, when used with insulin, could change the way people manage their disease," said Aaron Kowalski, the foundation's assistant vice president of treatment therapies. "Less insulin usage and fewer low blood sugar episodes would represent a significant improvement in quality of life for certain people living with type 1 diabetes today."
This will be the first study to investigate metreleptin in humans. Among other potential benefits, the team hopes to find that the hormone will lead to improved blood sugar control, which is one of the most common problems faced by individuals with type 1 diabetes.